Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Cor (NQ: EXAS )

53.49 +0.42 (+0.79%)
Streaming Delayed Price Updated: 1:15 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Cor

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
Which of these rebounding biotech stocks is the better buy right now? 
Via The Motley Fool
The Latest Analyst Ratings for Exact Sciences
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023
Via Benzinga
Could Exact Sciences Stock Help You Become a Millionaire?
The stock is full of potential -- and risk. 
Via The Motley Fool
1 Soaring Growth Stock to Buy and Hold for 10 Years
Moving forward, this company could perform much better than it did last year. 
Via The Motley Fool
Will Investors Notice Exciting Sign On Exact Sciences's Chart?
Via Benzinga
Is Exact Sciences a Buy?
The company's fast-growing business has loads of potential, but it may not be suitable for all investors. 
Via The Motley Fool
3 Growth Stocks That Are Off to Hot Starts in 2023
Are these stocks still good buys right now? 
Via The Motley Fool
7 AI Penny Stocks to Watch as a New Bull Market Emerges
Looking to profit off the current AI boom? Here are the most important AI penny stocks for investors to be watching. 
Via InvestorPlace
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
Five Best And Worst Performing Healthcare Stocks In January 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and... 
Via Talk Markets
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
Can gains in Tesla, Zoom, Exact Sciences, and other growth stocks set the stage for Cathie Woods' Ark Innovation Fund to stage a comeback in 2023? 
Via MarketBeat
Topics ETFs
Why Is Biophytis (BPTS) Stock Up 69% Today?
Biophytis (BPTS) stock is taking off on Thursday after the company released positive results from a Phase 2/3 clinical trial. 
Via InvestorPlace
Cathie Wood Is Doubling Down on This Hidden-Gem Artificial Intelligence Stock
Cathie Wood thinks Exact Sciences can ride the AI boom to the top. Here's what investors need to know about EXAS stock. 
Via InvestorPlace
Cathie Wood Trims Robinhood Stake As Stock Gains 28% In January — Also Offloads Shares In This Biotech Company
Cathie Wood-led ARK Investment Management sold 85,337 shares of financial services company Robinhood Markets Inc (NASDAQ: HOOD) at 
Via Benzinga
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec. 
Via Benzinga
Better Long-Term Buy in 2023: Exact Sciences or Veracyte?
As cancer screenings are becoming covered more often, both companies stand to gain. 
Via The Motley Fool
Cathie Wood Is Trouncing the Market So Far in 2023 Mainly Due to These 3 Stocks
Wood's ARK Innovation ETF is rebounding nicely. 
Via The Motley Fool
Don't Call It A Comeback: Cathie Wood Is Beating The S&P 500 In Early 2023
The competition could be paying the price in 2023 if Ark Invest can keep up with its early performance at the start of the year. 
Via Benzinga
48.8% of Cathie Wood's Portfolio Is in These 7 Stocks
The popular investment manager is attracted to innovative companies. 
Via The Motley Fool
Down 40% in 2022, Can Exact Sciences Recover in 2023?
Investors are attracted to its leading position in the market for early cancer detection, but the persistent losses its been reporting are enough to make anyone nervous. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
Cathie Wood Is Buying These Stocks, Should You?
Cathie Wood is known for her deep understanding of tech companies and for holding aggressive long positions in her tech funds. Let's look at what she's buying. 
Via MarketBeat
Topics ETFs
Bulls And Bears Of The Week: Tesla, Apple, Microsoft And Dogecoin Millionaire's Plan To Buy More Cardano
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
Sharp Tesla price cuts and some notable earnings were in focus. 
Via Investor's Business Daily
The Stocks Behind 2022's Popular ETFs
One of the most popular actively managed ETFs in 2022 for inflows was the JPMorgan Equity Premium Income ETF (JEPI). It holds 125 stocks and is currently paying a 12-month yield of 9.64%. 
Via Talk Markets
Cathie Wood Makes This Molecular Diagnostics Company Top Holding Of Ark Invest's Flagship Fund, Catapulting Past Zoom, Tesla
Shares of Exact Sciences, Inc. (NASDAQ: EXAS) have been on a tear, having gained over 27% in two sessions this week. 
Via Benzinga
Exact Sciences Corp Stock Price Is Trending Up Here's Why
Exact Science's stock price is shooting higher this week amid posting upward revisions for its revenue and earnings estimates for this quarter. 
Via MarketBeat
Exact Sciences Breaks Up From This Pattern, Signals Massive Reversal: Is A Bull Cycle In The Cards?
Exact Sciences Corp (NASDAQ: EXAS) gapped up more than 16% to start the trading day on Monday and continued to surge an additional 5.6% before hitting and rejecting a resistance area near $58.50. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.